UnknownNot Applicable

AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience

500 participantsStarted 2020-04-01

Plain-language summary

The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed diagnosis of COVID-19 Exclusion Criteria:

Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19

Timeframe: 6 months

NCT IDNCT04341103

SponsorCareDx

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-12-01

Alana Burns